RESUMEN
BACKGROUND: Patients' increasing interest in achieving optimal cosmetic outcomes and the widespread use of ultrathin ceramic veneers offer advantages such as high esthetic results and long-term durability. Several issues related to tooth preparation have been raised, including dental sensitivity, periodontal diseases, and increased treatment phases, in addition to complications associated with previous procedures, the treatment of which remains controversial to date. With the advancement of dental ceramic and its manufacturing techniques, it was widely used to manufacture ultrathin ceramic veneers with minimal preparation. Issues such as fracture and abfraction are the most common in ceramic veneers made of feldspathic ceramic due to their weak mechanical properties against various forces, which led to the emergence of lithium disilicate glass-ceramic manufactured using the heat-press technique. This has resulted in ultrathin ceramic veneers with a thickness of up to 0.1-0.2 mm easily bonded and finished as they have high mechanical properties and esthetic qualities that mimic natural tooth color and shape. The current cohort study aimed to evaluate the success rates of this kind of treatment for patients treated at our department. MATERIALS AND METHODS: This observational cohort study's sample comprised 60 ultrathin ceramic veneers manufactured from lithium disilicate glass-ceramic bonded to nonprepared upper teeth. The clinical performance of the studied sample was evaluated and monitored at monthly intervals (one month, three months, six months, and one year) using the clinical success evaluation based on Walton's principles adopted for evaluating the success and failure of fixed restorations. RESULTS: Ultrathin ceramic veneers made from lithium disilicate glass-ceramic, bonded to nonprepared teeth, proved to be a successful clinical and esthetic treatment option, with a clinical success rate of 100% during the entire follow-up period. CONCLUSIONS: This study's findings indicate that ultrathin ceramic veneers made from lithium disilicate glass-ceramic, bonded to nonprepared teeth, are a successful clinical and esthetic treatment option, with a clinical success rate of 100% during the entire follow-up period.
RESUMEN
BACKGROUND: Urinary tract infections (UTIs) are currently posing a worldwide health concern by affecting millions of people. The genetic variant rs2234671 in the CXCR1-interleukin-8 receptor is closely related to a raised UTI risk. OBJECTIVES: In this work, the impact of CXCR1 (rs2234671) on UTI individuals was examined. METHODS: The demographic features of 30 recurrent UTI patients and 20 controls were thoroughly investigated. Bacterial isolation and identification were performed by the implementation of cultural and biochemical methods. DNA extraction, purification of all samples from both patients and healthy people, and IL-8 rs2234671 (C/G) SNP genotyping using T-ARMS-PCR were performed. The significance of the results was evaluated by carrying out a statistical analysis. FINDINGS: The patient's average age was 34.63 ± 11.44 years, and controls averaged 30.30 ± 8.59 years (P= 0.156). No significant gender difference existed (P= 0.804). Escherichia coli (63.3%) was predominant, followed by Proteus mirabilis (26.7%), Enterococcus faecalis (23.3%), Klebsiella pneumoniae (10.0%), and Pseudomonas aeruginosa (20.0%). No significant association was found between bacterial species frequency, age, or sex. From the CXCR1 (rs2234671) frequency comparison, a higher GG genotype incidence in UTI patients than controls was extracted (26.7% vs. 15.0%), though not statistically significant. Risk analysis revealed that GG homozygous and C/G heterozygous genotypes were not UTI risk factors (OR = 2.47 and OR = 1.85, respectively). Moreover, the allele frequencies displayed no significant difference between the patients and controls (G allele: 66.7% vs. 66.7%; C allele: 33.3% vs. 33.3%). MAIN CONCLUSIONS: Although no significant association between CXCR1 (rs2234671) and UTI was found, the GG genotype may point to the increasing probability of UTI risk. Additional research is required to confirm and expand these conclusions.
Asunto(s)
Infecciones Urinarias , Adulto , Humanos , Persona de Mediana Edad , Adulto Joven , Alelos , Frecuencia de los Genes/genética , Genotipo , Factores de Riesgo , Infecciones Urinarias/genética , Infecciones Urinarias/microbiologíaRESUMEN
BACKGROUND: Recurrent aphthous stomatitis (RAS) is an autoimmune disease that affects 25% of the population, with no cure until now. Intralesional triamcinolone acetonide (TA) injections are an effective classic treatment for RAS; and, more recently, intralesional platelet rich plasma (PRP) has been used to manage oral lesions of some autoimmune diseases. OBJECTIVES: To try intralesional PRP injections in the management of recurrent oral ulceration of Behcet's disease and compare their clinical effect with intralesional TA injections; and to study the effects of both treatments on the serum level of interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α. METHODS: Thirty patients diagnosed with RAS were recruited for this trial, with a male to female ratio of 1:1, and ages ranging from 12 to 66 years. For 6 months, 15 patients were treated monthly with intralesional PRP injections and the other 15 were treated monthly with intralesional TA injections. The clinical effects of both treatments were registered in the oral clinical manifestation index (OCMI), as were their effects on the serum levels of IL-1β, IL-6, and TNF-α. RESULTS: The OCMI of PRP-treated patients initially ranged from 8 to 23 with a mean±SD of (13.5±4.6). This mean decreased to 5.7 by the end of month 6, with a statistically highly significant P-value compared with baseline. The OCMI of TA-treated patients initially ranged from 8 to 20 with a mean±SD of (13.5±3.8). This mean decreased to 10.5 by the end of month 6, with a statistically significant P-value compared with baseline. Both treatments significantly decreased the serum levels of IL-1β, while only PRP significantly decreased the TNF-α. CONCLUSION: Intralesional PRP injections are a new, safe, and effective treatment for RAS. J Drugs Dermatol. 2023;22(4): doi:10.36849/JDD.7218 Citation: Kadhim MAA, Musa HD, Barzanji HAA. The effectiveness of intralesional platelet rich plasma in recurrent aphthous stomatitis in comparison with triamcinolone acetonide. J Drugs Dermatol. 2023;22(4):398-403. doi:10.36849/JDD.7218.